A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)-Reference-Cited by-同舟云学术

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)

Published:2019-09 Issue:3 Volume:71 Page:498-504
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Wilson Eleanor^ORCID,Covert Emily,Hoffmann Jennifer,Comstock Emily,Emmanuel Benjamin,Tang Lydia^ORCID,Husson Jennifer,Chua Joel^ORCID,Price Angie,Mathur Poonam,Rosenthal Elana^ORCID,Kattakuzhy Sarah,Masur Henry,Kottilil Shyam

Funder

Gilead Sciences, Inc

Intramural Research Program of the NIH

Publisher

Elsevier BV

Subject

Hepatology

Reference17 articles.

1. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs;Naggie;Annu Rev Med,2017

2. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials;Arias;Antivir Ther,2017

3. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population;Tang;J Viral Hepat,2018

4. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study;Tapper;J Viral Hepat,2017

5. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Polaris Observatory;Lancet Gastroenterol Hepatol,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C virus eradication in people living with human immunodeficiency virus: Where are we now?;World Journal of Hepatology;2024-05-27

2. Personalized care approaches to hepatitis C therapy: recent advances and future directions;Expert Review of Anti-infective Therapy;2024-03-11

3. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

4. Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct acting anti-virals, but salvage therapy may be life-saving;Infectious Diseases;2023-08-10

5. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan;Hepatology International;2023-01-26